Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (2)
P 1 (1)
P 4 (1)

Trial Status

Recruiting2
Not Yet Recruiting2
Active Not Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06999109Not ApplicableNot Yet Recruiting

Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress

NCT05879419Phase 4Active Not Recruiting

Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases

NCT07374107Recruiting

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

NCT07349667Not ApplicableNot Yet Recruiting

Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting

NCT06686524Phase 1RecruitingPrimary

Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)

Showing all 5 trials

Research Network

Activity Timeline